Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BCAX vs AVBP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BCAX Captures Overall Composite Edge (52.1 HOLD vs 43.7 HOLD), While AVBP Leads 5–0 on Growth & Valuation Pillars

BCAX Overall Winner 6-Pillar Tally: BCAX 0 – 5 AVBP (1 Tie) Matrix Metrics: BCAX 3 – 2 AVBP

As of Nov 16, 2026, Bicara Therapeutics Inc. (BCAX) captures the overall head-to-head institutional edge over ArriVent BioPharma, Inc. (AVBP) on higher Unified Composite conviction (52.1/100 HOLD vs. 43.7/100 HOLD) after splitting the core matrix 3–2 (led by composite factor balance), while AVBP wins 5–0 across the 6-pillar growth and valuation breakdown. BCAX trades at $9.58 (N/M Forward P/E, 0.0% operating margin) versus AVBP at $11.98 (N/M Forward P/E, -3620.0% operating margin).

  • Growth vs. Quality Trade-Off: BCAX earns the overall head-to-head edge with a stronger Unified Composite Score (52.1/100 HOLD vs. AVBP 43.7/100 HOLD) and 1.41β · 184% Vol risk profile, whereas AVBP leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: BCAX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.7); meanwhile AVBP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BCAX vs AVBP
BCAX NASDAQ Head-to-Head Winner
Bicara Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$9.58
-4.39% 1D
Market Cap $671.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.41β · 184% Vol
Unified Composite Score
52.1 / 100 HOLD
Tech 58.0 Fund 66.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -23.1%), weak momentum, RSI 33
RSI-14: 32.7 · SMA20: $11.85 · SMA50: $16.57
AVBP NASDAQ
ArriVent BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$11.98
-7.92% 1D
Market Cap $676.0M
TTM Revenue $5.0M
Forward P/E N/M
Beta / 30D Vol 1.27β · 128% Vol
Unified Composite Score
43.7 / 100 HOLD
Tech 33.0 Fund 57.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -22.5%), weak momentum, RSI 31
RSI-14: 30.8 · SMA20: $15.02 · SMA50: $20.98

6-Pillar Scorecard Institutional Category Breakdown (BCAX 0 – 5 AVBP)

Columns: Metric · BCAX · AVBP
1. Valuation Multiples AVBP
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 112.5x
2. Growth & Scale AVBP
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $5.0M
Market Cap $671.2M $676.0M
3. Profitability & Quality AVBP
Gross Margin N/A 100.0%
Operating Margin 0.0% -3620.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -54.2% -48.7%
4. Balance Sheet & Cash Flow AVBP
Cash Generation (TTM) -$163M -$153M
Cash Flow Margin N/A N/A
Net Cash / Leverage $81M Net Cash $113M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AVBP
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 102.7% (23rd %ile) 88.5% (6th %ile)
Put/Call OI Skew N/A 0.16x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Markdown ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BCAX (3) vs AVBP (2)
Institutional Metric BCAX AVBP Criterion Row Edge
Market Capitalization
Scale
$671.2M $676.0M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% -3620.0% Higher Margin BCAX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-54.2% -48.7% Higher ROE AVBP
52-Week Range Position
Momentum
7% ($8–$31) 2% ($11–$36) Stronger Trend BCAX
Beta / 30D Volatility
Risk Regime
1.41β · 184% Vol 1.27β · 128% Vol Lower Realized Risk AVBP
Unified Institutional Score
Composite Signal
52.1 / 100 (HOLD) 43.7 / 100 (HOLD) Higher Composite BCAX
Trailing 12M Revenue (USD)
Operating Scale
N/A $5.0M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 112.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$163M ($81M Net Cash) -$153M ($113M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AVBP +14.82 pp
BCAX: -42.91% · AVBP: -28.09%
3M Horizon AVBP +1.49 pp
BCAX: -61.56% · AVBP: -60.07%
6M Horizon BCAX +5.36 pp
BCAX: -50.34% · AVBP: -55.7%
1Y Horizon BCAX +6.31 pp
BCAX: -32.82% · AVBP: -39.13%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BCAX vs AVBP. Trailing 12-month operating profitability (BCAX 0.0% vs AVBP -3620.0%) and valuation multiples (BCAX N/M vs AVBP N/M Forward P/E) are benchmarked directly in Pillar 4 below.

BCAX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-54.2% · N/M
AVBP ADR TTM Benchmark FX-Normalized USD
TTM Revenue$5.0M
Gross Margin100.0%
Op. Margin-3620.0%
ROE / Fwd P/E-48.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BCAX BREAKDOWN
93d in phase · OBV ACCUMULATION
Current IV 102.7%
IV Percentile 23rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact BCAX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AVBP BREAKDOWN
102d in phase · OBV ACCUMULATION
Current IV 88.5%
IV Percentile 6th %ile
Put/Call OI Skew 0.16x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact AVBP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BCAX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $671.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AVBP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $676.0M market capitalization and -3620.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BCAX vs AVBP Key Questions & Quantitative Answers

As of Nov 16, 2026, Bicara Therapeutics Inc. (BCAX) captures the overall head-to-head institutional edge over ArriVent BioPharma, Inc. (AVBP) on higher Unified Composite conviction (52.1/100 HOLD vs. 43.7/100 HOLD) after splitting the core matrix 3–2 (led by composite factor balance), while AVBP wins 5–0 across the 6-pillar growth and valuation breakdown. BCAX trades at $9.58 (N/M Forward P/E, 0.0% operating margin) versus AVBP at $11.98 (N/M Forward P/E, -3620.0% operating margin). Growth vs. Quality Trade-Off: BCAX earns the overall head-to-head edge with a stronger Unified Composite Score (52.1/100 HOLD vs. AVBP 43.7/100 HOLD) and 1.41β · 184% Vol risk profile, whereas AVBP leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: BCAX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.7); meanwhile AVBP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AVBP leads the Growth & Scale pillar: BCAX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with AVBP at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $5.0M TTM revenue (100.0% gross margin, -3620.0% operating margin). On trailing 12-month operating scale, BCAX generates N/A in USD-normalized revenue versus $5.0M for AVBP. In operating R&D and SG&A reinvestment, BCAX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AVBP.

AVBP screens cheaper on headline valuation multiples. BCAX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas AVBP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 112.5x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BCAX (-54.2% ROE) versus AVBP (-48.7% ROE) capital efficiency.

In options market volatility and institutional positioning, BCAX carries 102.7% implied volatility (23rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.41β · 184% Vol realized risk). By comparison, AVBP carries 88.5% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.16x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.27β · 128% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.